Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer

ICIs offer clinical benefit in advanced endometrial cancer, particularly in dMMR tumors. First-line ICI + chemotherapy appears cost-effective for dMMR at U.S. WTP levels. However, use in pMMR or second-line settings may require drug price reductions or biomarker-based selection to be economically viable.

Authors

Institutions

Publication Details

Journal
Gynecologic Oncology Reports
Published
2025-05-05
DOI
https://doi.org/10.1016/j.gore.2025.101761
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer

Katsuaki Inami
Gynecologic Oncology Reports
Endometrial and Cervical Cancer Treatments
article

Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer

Katsuaki Inami
article en

Abstract

ICIs offer clinical benefit in advanced endometrial cancer, particularly in dMMR tumors. First-line ICI + chemotherapy appears cost-effective for dMMR at U.S. WTP levels. However, use in pMMR or second-line settings may require drug price reductions or biomarker-based selection to be economically viable.

Gynecologic Oncology ReportsVol. 59
Fujieda Municipal General Hospital (JP), Morinomiya Hospital (JP)
Good health and well-being
Openalex Percentile: Top 87%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.